Search results
Moderna Just Gave Investors Another Reason to Buy the Stock | The Motley Fool
The Motley Fool· 4 days agoModerna (MRNA -3.58%) is best known for its work in the coronavirus vaccine market. Let's look...
Moderna says next-gen COVID shot effective in study
BioPharma Dive via Yahoo Finance· 7 days agoTrial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases...
Moderna Stock (NASDAQ:MRNA): Is There Life Beyond Disease Outbreaks?
TipRanks via Yahoo Finance· 3 days agoModerna (NASDAQ:MRNA) stock has surged 40.8% since the turn of the year. Some of this momentum can...
Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Wellington Management Group LLP
ETF DAILY NEWS· 3 days agoWellington Management Group LLP lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 28.8% in the 4th quarter, according to the company in its most ...
Moderna's mRNA-1283 vaccine shows promise in Phase 3 trial By Investing.com
Investing.com· 7 days agoModerna , Inc. (NASDAQ:MRNA) has announced successful results from the Phase 3 trial of its...
Gateway - Quartz
Quartz· 1 day agoModerna said Tuesday that its updated COVID-19 vaccine demonstrated a stronger immune response than its current jab in results from a phase-3 clinical trial. The pharma < ...
Moderna stock is lone omen of bird flu pandemic
Reuters· 3 days agoThe recent rise of Moderna’s stock tells a grim tale. The $56 billion company which pioneered a Covid vaccine has seen its market value rise 40% since...
Moderna says new-generation COVID vaccine more effective than Spikevax in adults 18 and over
Morningstar· 7 days agoModerna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher efficacy in adults age 18 and older compared with its ...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation...
Digital Journal· 7 days agomRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and olderHigher efficacy was observed in mRNA-1283 compared
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. -...
FOX 23 News Albany· 5 days agoPomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA). Such investors are advised to ...